What are Mirum Pharmaceuticals, Inc.'s total assets?

Mirum Pharmaceuticals, Inc. (MIRM) holds $890.9M in total assets, up 29.1% year over year.

How much debt does Mirum Pharmaceuticals, Inc. have?

Mirum Pharmaceuticals, Inc. carries $13.5M in total debt against $242.5M of shareholders' equity, a debt-to-equity ratio of 0.06.

How much cash does Mirum Pharmaceuticals, Inc. have?

Mirum Pharmaceuticals, Inc. holds $261.5M in cash and equivalents.

Can Mirum Pharmaceuticals, Inc. cover its short-term obligations?

Its current ratio is 2.09 — current assets exceed current liabilities.

Where does Mirum Pharmaceuticals, Inc.'s balance sheet data come from?

Every line is extracted from Mirum Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Mirum Pharmaceuticals, Inc. MIRM Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$254.38M+25.3%	$202.97M-27.0%	$278.12M+893%	$28M-10.6%
Short-term investments	$86.64M+49.9%	$57.81M—	$0-100%	$123.72M-1.2%
Restricted cash	$1.48M+249%	$425K—	$0-100%	$100M—
Accounts receivable, net	$123.33M+57.5%	$78.29M+15.2%	$67.97M+183%	$23.99M+634%
Inventories	$94.27M+9.6%	$86.04M+44.2%	$59.68M+221%	$18.61M+1,130%
Raw materials	$2.9M-4.4%	$3.03M+1.1%	$3M—	——
Work in process	$18.47M+14.8%	$16.09M+63.0%	$9.87M—	——
Finished goods	$3.52M+7.1%	$3.28M-65.2%	$9.44M—	——
Prepaid expenses and other current assets	$18.14M+53.9%	$11.78M+7.8%	$10.94M+22.2%	$8.95M+69.7%
Total current assets	$549.68M+39.9%	$392.79M+1.4%	$387.54M+104%	$190.23M+14.2%
Property and equipment, net	$1.86M+63.5%	$1.14M+61.3%	$706K-22.8%	$914K-6.8%
Accumulated depreciation	$60.67M+65.0%	$36.77M+169%	$13.67M—	——
Operating lease right-of-use assets	874,100,000%+6,600,000%	867,500,000%+739,100,000%	128,400,000%-14,700,000%	143,100,000%-13,800,000%
Intangible assets, net	$260.92M+4.4%	$249.82M-1.2%	$252.93M+329%	$58.95M+215%
Other non-current assets	$0-100%	$5.38M+29.2%	$4.17M+201%	$1.38M-22.6%
Equity method investments	$8.11M-35.3%	$12.53M—	$0—	$0-100%
Available-for-sale securities	$8.11M-35.3%	$12.53M—	——	——
Total assets	$842.81M+25.7%	$670.75M+3.7%	$646.62M+83.2%	$352.91M+19.8%
Accounts payable	$9.61M-34.2%	$14.62M+97.1%	$7.42M-14.7%	$8.69M-5.2%
Accrued expenses	$47.28M+46.6%	$32.25M-58.9%	$78.54M+45.4%	$54.02M+75.8%
Operating lease liabilities, current	$2.14M+25.2%	$1.71M+54.8%	$1.1M+18.6%	$931K+30.9%
Contract liabilities	$3.6M—	——	——	——
Accrued interest	$2.11M0.0%	$2.11M0.0%	$2.11M—	——
Total current liabilities	$205.8M+62.6%	$126.55M+45.4%	$87.06M+34.5%	$64.73M+52.0%
Operating lease liabilities, non-current	$7.52M-5.7%	$7.97M+1,192%	$617K-50.9%	$1.26M-33.9%
Operating Lease Liabilities (Total)	$9.66M-0.3%	$9.68M+463%	$1.72M-21.3%	$2.19M-16.3%
Other non-current liabilities	$5.01M+99.7%	$2.51M-34.8%	$3.85M-15.1%	$4.53M+26,559%
Total liabilities	$528.12M+18.6%	$445.11M+11.9%	$397.95M+88.7%	$210.87M+20.9%
Preferred stock	$0—	$0—	$0—	$0—
Common stock	200M+3,999,900%	5K0.0%	5K+25.0%	4K+33.3%
Additional paid-in capital	$981.88M+12.8%	$870.19M+8.3%	$803.26M+50.1%	$535.07M+41.8%
Retained earnings	-$667.54M-3.6%	-$644.18M-15.8%	-$556.24M-41.6%	-$392.82M-52.8%
Accumulated other comprehensive income (loss)	$351K+194%	-$373K-123%	$1.64M+858%	-$217K-520%
Total stockholders' equity	$314.69M+39.5%	$225.64M-9.3%	$248.67M+75.1%	$142.04M+18.2%
Total liabilities and stockholders' equity	$842.81M+25.7%	$670.75M+3.7%	$646.62M+83.2%	$352.91M+19.8%
Available-for-Sale Debt Securities - Amortized Cost	$348.99M—	——	——	——
Available-for-Sale Debt Securities - Fair Value by Maturity	——	——	——	——
Available-for-Sale Debt Securities - Single Maturity Date	——	——	——	——
Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months)	——	$0—	$0—	——
AFS and Trading Securities - Unrealized Loss Position (>=12 Months)	——	$0—	$0—	——
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value	——	$0—	$0—	——
Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)	$298.17M+33.7%	$222.93M-22.1%	$286.33M+124%	$128M—
Cash, Cash Equivalents, and Marketable Securities	$349.13M—	——	——	——
Available For Sale Securities Debt Securities Current	$86.64M+49.9%	$57.81M—	——	——
Raw materials and supplies inventory, gross	$2.9M-4.4%	$3.03M+1.1%	$3M—	——
Deferred Tax Assets and Other Non-Current Assets	$12.02M+123%	$5.38M+29.2%	$4.17M+201%	$1.38M-22.6%
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	——	——	——	——
Finite Lived Intangible Assets - Gross	$321.59M+12.2%	$286.59M+7.5%	$266.59M—	——
Investments - Amortized Cost Basis	$348.99M—	——	——	——
Net Investment in Lease	$8.74M+0.8%	$8.68M+576%	$1.28M-10.3%	$1.43M-8.8%
Long-term marketable securities	$8.11M-35.3%	$12.53M—	——	——
Intangible assets — net	$260.92M+4.4%	$249.82M-1.2%	$252.93M—	——
Other intangible assets—net	$260.92M+4.4%	$249.82M-1.2%	$252.93M+329%	$58.95M+215%
Investments and Cash	——	——	——	——
Investments	$8.11M-35.3%	$12.53M—	$0—	$0-100%
Operating lease right-of-use assets	$8.74M+0.8%	$8.68M+576%	$1.28M-10.3%	$1.43M-8.8%
Other non-current assets	$12.02M+123%	$5.38M+29.2%	$4.17M+201%	$1.38M-22.6%
Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)	$86.64M+49.9%	$57.81M—	$0-100%	$123.72M-1.2%
Operating Lease Right-of-Use Assets in Other Assets	$8.74M+0.8%	$8.68M+576%	$1.28M-10.3%	$1.43M-8.8%
Software and Technology Licenses, Net	$12.02M+123%	$5.38M+29.2%	$4.17M+201%	$1.38M-22.6%
Accrued Manufacturing Costs	$47.28M+46.6%	$32.25M+54.0%	$20.94M—	——
Accrued Royalties (Current)	$16.21M+73.1%	$9.36M+39.4%	$6.72M—	——
Accrued expenses and other current liabilities	$196.19M+75.3%	$111.93M—	——	——
Compensation and benefits	$47.28M+46.6%	$32.25M+54.0%	$20.94M—	——
Lease Liability Payments - 2020 (Remaining Three Months)	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	——	——	——	——
Lease Liability Payments - Due Year Two	——	——	——	——
Lease Liability Payments - Due Year Three	——	——	——	——
Lease Liability Payments - Due Year Four	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	——	——	——	——
Operating Lease Liability Payments Due	——	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	——	——	——	——
Professional Service Fees Payable	$17.29M+37.8%	$12.55M+58.0%	$7.94M—	——
Convertible Debt (Non-Current)	$309.8M+0.6%	$308.08M+0.5%	$306.42M—	$0—
Operating Lease Liability Payments - 2026 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2027 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2028 (Lessee)	——	——	——	——
Total debt	$9.66M-0.3%	$9.68M+463%	$1.72M-21.3%	$2.19M-16.3%
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Accumulated Loss	——	$0—	$0—	——
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.00—	——
Common Stock Shares Issued	51.9M+7.4%	48.3M+3.5%	46.7M—	——
Convertible Preferred Stock Authorized Shares	10M0.0%	10M0.0%	10M—	——
Convertible Preferred Stock Issued Shares	0—	0—	0—	——
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	——
Additional paid-in capital	$981.88M+12.8%	$870.19M+8.3%	$803.26M+50.1%	$535.07M+41.8%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$5K0.0%	$5K0.0%	$5K+25.0%	$4K+33.3%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.00—	——
Shares Reserved for Future Issuance Under Stock Plans	——	——	24.1M—	——
Unrealized Gains on Investments	$140K—	——	——	——
Unrealized Losses on Investments (Before Tax)	$0—	——	——	——
Cumulative Cost Basis	$348.99M—	——	——	——
Fair Value Measurement Disclosure	——	——	——	——
Accrued clinical trials	$13.96M+95.3%	$7.15M-1.7%	$7.27M—	——
Accrued contract manufacturing and non-clinical costs	$8.72M+15.4%	$7.56M-23.9%	$9.92M—	——
Accrued loss on firm purchase commitments	$2.11M+11.0%	$1.9M—	——	——
Noncurrent accrued loss on firm purchase commitments	$1.43M-43.2%	$2.51M—	——	——
Accrued milestone payment	$35M—	——	——	——
Professional service fees	$17.29M+37.8%	$12.55M+58.0%	$7.94M—	——
Licensing Arrangements	$16.21M+73.1%	$9.36M+39.4%	$6.72M—	——
Noncurrent accrued sales deductions	$3.59M—	$0—	——	——
Accrued sales deductions and other	$51.38M—	——	——	——
Contingent liabilities	$0—	——	——	——
Asset Acquisition Contingent Consideration Liability Noncurrent	$0—	——	——	——
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$0—	——	——	——
Gross Unrealized Gains	$140K—	——	——	——
Total	$348.99M—	——	——	——
Due in 1 year or less	——	——	——	——
Available for sale investments	$349.13M—	——	——	——
Cash and cash equivalents, end of period	$298.17M+33.7%	$222.93M-22.1%	$286.33M+124%	$128M—
Cash Equivalents And Available For Sale Securities Debt Securities	$349.13M+27.7%	$273.3M-1.7%	$278.12M—	——
Common stock, capital shares reserved for future issuance	——	——	$24.15M—	——
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$0—	——
Common stock, shares authorized (in shares)	$200M0.0%	$200M0.0%	$200M—	——
Common stock, shares issued (in shares)	$51.9M+7.4%	$48.34M+3.5%	$46.72M—	——
Common Stock, Shares, Outstanding	$51.9M+7.4%	$48.34M+3.5%	$46.72M—	——
Contract with Customer, Asset, after Allowance for Credit Loss	$0—	——	——	——
Contract with Customer, Liability	$3.6M—	——	——	——
Long-term debt, net	$309.8M+0.6%	$308.08M+0.5%	$306.42M—	$0—
12 months or more	——	$0—	$0—	——
One to two years	——	——	——	——
Finite-Lived Intangible Assets, Accumulated Amortization	$60.67M+65.0%	$36.77M+169%	$13.67M—	——
2028	——	——	——	——
2030	——	——	——	——
Remainder of 2026	——	——	——	——
2027	——	——	——	——
2029	——	——	——	——
Thereafter	——	——	——	——
Gross Carrying Amount	$321.59M+12.2%	$286.59M+7.5%	$266.59M—	——
Lessee Operating Lease Liability Payments Due	——	——	——	——
Thereafter	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	——	——	——	——
Operating Lease Weighted Average Discount Rate Percent	——	——	——	——
Ownership maximum threshold percentage	——	——	——	——
Ownership threshold percentage	——	——	——	——
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$0—	——
Preferred Stock, Shares Authorized	$10M0.0%	$10M0.0%	$10M—	——
Preferred Stock, Shares Issued	$0—	$0—	$0—	——
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	——
Remainder of Fiscal Year 2024	——	——	——	——
Remainder of Fiscal Year 2025	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Mirum Pharmaceuticals, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Mirum Pharmaceuticals, Inc.'s total assets?: Mirum Pharmaceuticals, Inc. (MIRM) holds $890.9M in total assets, up 29.1% year over year.
How much debt does Mirum Pharmaceuticals, Inc. have?: Mirum Pharmaceuticals, Inc. carries $13.5M in total debt against $242.5M of shareholders' equity, a debt-to-equity ratio of 0.06.
How much cash does Mirum Pharmaceuticals, Inc. have?: Mirum Pharmaceuticals, Inc. holds $261.5M in cash and equivalents.
Can Mirum Pharmaceuticals, Inc. cover its short-term obligations?: Its current ratio is 2.09 — current assets exceed current liabilities.
Where does Mirum Pharmaceuticals, Inc.'s balance sheet data come from?: Every line is extracted from Mirum Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.